JP2004536074A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004536074A5 JP2004536074A5 JP2003500059A JP2003500059A JP2004536074A5 JP 2004536074 A5 JP2004536074 A5 JP 2004536074A5 JP 2003500059 A JP2003500059 A JP 2003500059A JP 2003500059 A JP2003500059 A JP 2003500059A JP 2004536074 A5 JP2004536074 A5 JP 2004536074A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- branched
- linear
- general formula
- atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 18
- 239000012453 solvate Substances 0.000 claims 18
- -1 methylenedioxy group Chemical group 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 6
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 6
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000004434 sulfur atom Chemical group 0.000 claims 6
- 125000002541 furyl group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000001544 thienyl group Chemical group 0.000 claims 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 208000010412 Glaucoma Diseases 0.000 claims 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000004224 protection Effects 0.000 claims 4
- 239000002464 receptor antagonist Substances 0.000 claims 4
- 229940044551 receptor antagonist Drugs 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 206010006482 Bronchospasm Diseases 0.000 claims 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000000059 Dyspnea Diseases 0.000 claims 2
- 206010013975 Dyspnoeas Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 229960005305 adenosine Drugs 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 230000003288 anthiarrhythmic effect Effects 0.000 claims 2
- 230000001088 anti-asthma Effects 0.000 claims 2
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 230000002253 anti-ischaemic effect Effects 0.000 claims 2
- 230000000648 anti-parkinson Effects 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 239000003416 antiarrhythmic agent Substances 0.000 claims 2
- 239000000924 antiasthmatic agent Substances 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 239000000939 antiparkinson agent Substances 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 230000007885 bronchoconstriction Effects 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 230000016396 cytokine production Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 210000003979 eosinophil Anatomy 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 210000003630 histaminocyte Anatomy 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000004410 intraocular pressure Effects 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 238000013508 migration Methods 0.000 claims 2
- 230000005012 migration Effects 0.000 claims 2
- 230000009251 neurologic dysfunction Effects 0.000 claims 2
- 208000015015 neurological dysfunction Diseases 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 239000002664 nootropic agent Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 231100000572 poisoning Toxicity 0.000 claims 2
- 230000000607 poisoning effect Effects 0.000 claims 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 claims 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- FTQWRYSLUYAIRQ-UHFFFAOYSA-N n-[(octadecanoylamino)methyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCNC(=O)CCCCCCCCCCCCCCCCC FTQWRYSLUYAIRQ-UHFFFAOYSA-N 0.000 claims 1
- XSWSGVCWMTYDHC-UHFFFAOYSA-N n-[3-cyano-4-(furan-2-ylmethylamino)quinolin-2-yl]furan-2-carboxamide Chemical compound C=1C=COC=1C(=O)NC(C=1C#N)=NC2=CC=CC=C2C=1NCC1=CC=CO1 XSWSGVCWMTYDHC-UHFFFAOYSA-N 0.000 claims 1
- JAPZLARAKVKDGB-UHFFFAOYSA-N n-[3-cyano-4-(furan-2-ylmethylamino)quinolin-2-yl]thiophene-3-carboxamide Chemical compound C1=CSC=C1C(=O)NC(C=1C#N)=NC2=CC=CC=C2C=1NCC1=CC=CO1 JAPZLARAKVKDGB-UHFFFAOYSA-N 0.000 claims 1
- RBVFCHLFDTUSCP-UHFFFAOYSA-N n-[3-cyano-4-(thiophen-2-ylmethylamino)quinolin-2-yl]thiophene-3-carboxamide Chemical compound C1=CSC=C1C(=O)NC(C=1C#N)=NC2=CC=CC=C2C=1NCC1=CC=CS1 RBVFCHLFDTUSCP-UHFFFAOYSA-N 0.000 claims 1
- SPDQSSIORISFDN-UHFFFAOYSA-N n-[4-(benzylamino)-3-cyanoquinolin-2-yl]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NC=2C(=C(NCC=3C=CC=CC=3)C3=CC=CC=C3N=2)C#N)=C1 SPDQSSIORISFDN-UHFFFAOYSA-N 0.000 claims 1
- JMMDWIFCQSCQSV-UHFFFAOYSA-N n-[4-(benzylamino)-3-cyanoquinolin-2-yl]thiophene-3-carboxamide Chemical compound C1=CSC=C1C(=O)NC(C=1C#N)=NC2=CC=CC=C2C=1NCC1=CC=CC=C1 JMMDWIFCQSCQSV-UHFFFAOYSA-N 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0102279A HUP0102279A3 (en) | 2001-05-31 | 2001-05-31 | A3 antagonist amino-quinoline-derivatives, process for their preparation, pharmaceutical compositions containing them and their use |
| HU0200774A HUP0200774A2 (hu) | 2002-03-01 | 2002-03-01 | Amino-piridin és amino-kinolin származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és intermedierjeik |
| PCT/HU2002/000048 WO2002096879A1 (en) | 2001-05-31 | 2002-05-29 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004536074A JP2004536074A (ja) | 2004-12-02 |
| JP2004536074A5 true JP2004536074A5 (enExample) | 2005-12-22 |
| JP4409935B2 JP4409935B2 (ja) | 2010-02-03 |
Family
ID=47711452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003500059A Expired - Fee Related JP4409935B2 (ja) | 2001-05-31 | 2002-05-29 | アミノキノリンおよびアミノピリジン誘導体およびそのアデノシンａ３リガンドとしての使用 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6969723B2 (enExample) |
| EP (1) | EP1390349B1 (enExample) |
| JP (1) | JP4409935B2 (enExample) |
| KR (1) | KR100745307B1 (enExample) |
| CN (1) | CN1257160C (enExample) |
| AR (1) | AR036074A1 (enExample) |
| AU (1) | AU2002304358B2 (enExample) |
| BG (1) | BG108477A (enExample) |
| BR (1) | BR0209719A (enExample) |
| CA (1) | CA2448561C (enExample) |
| CO (1) | CO5550457A2 (enExample) |
| CZ (1) | CZ20033510A3 (enExample) |
| EA (1) | EA006854B1 (enExample) |
| EE (1) | EE05304B1 (enExample) |
| HR (1) | HRP20031091B1 (enExample) |
| IL (1) | IL158854A0 (enExample) |
| IS (1) | IS2773B (enExample) |
| MA (1) | MA26236A1 (enExample) |
| MX (1) | MXPA03010870A (enExample) |
| NO (1) | NO327710B1 (enExample) |
| NZ (1) | NZ529966A (enExample) |
| PL (1) | PL366516A1 (enExample) |
| RS (1) | RS95003A (enExample) |
| RU (1) | RU2278112C2 (enExample) |
| SK (1) | SK14142003A3 (enExample) |
| TN (1) | TNSN03117A1 (enExample) |
| WO (1) | WO2002096879A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| US8729107B2 (en) * | 2002-12-06 | 2014-05-20 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
| WO2004052291A2 (en) | 2002-12-06 | 2004-06-24 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
| RU2317290C2 (ru) * | 2003-07-31 | 2008-02-20 | Санофи-Авентис | Производные аминохинолина и их применение в качестве лигандов аденозина а3 |
| PL1663982T3 (pl) * | 2003-07-31 | 2008-03-31 | Sanofi Aventis | Pochodne aminochinoliny i ich zastosowanie jako ligandów adenozyny A3 |
| HUP0400812A2 (en) * | 2004-04-19 | 2006-02-28 | Sanofi Aventis | Crystalline forms of 2-amino-3-cyano-quinoline derivatives, process for their preparation and pharmaceutical compositions containing them |
| WO2006040645A1 (en) * | 2004-10-11 | 2006-04-20 | Ranbaxy Laboratories Limited | N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma |
| HUP0402371A2 (en) * | 2004-11-15 | 2006-09-28 | Sanofi Aventis | Novel 125-i-labeled amino-quinoline derivatives |
| KR100788161B1 (ko) * | 2006-01-06 | 2007-12-21 | (주)아모레퍼시픽 | 벤즈이미다졸 아민 유도체 또는 아미노퀴놀린 유도체를 함유하는 피부 미백용 조성물 |
| HUP0700395A2 (en) * | 2007-06-07 | 2009-03-02 | Sanofi Aventis | Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates |
| KR101106050B1 (ko) * | 2009-03-25 | 2012-01-18 | 한국과학기술연구원 | 아미노퀴놀린 화합물, 이의 제조 방법 및 이를 함유하는 의약 조성물 |
| WO2012030918A1 (en) * | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Adenosine a3 receptor modulating compounds and methods of use thereof |
| WO2012166654A1 (en) * | 2011-05-27 | 2012-12-06 | The Regents Of The University Of California | Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof |
| CA2754237A1 (en) | 2011-05-27 | 2012-11-27 | The Regents Of The University Of California | Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof |
| ES2578363B1 (es) | 2015-01-22 | 2017-01-31 | Palobiofarma, S.L. | Moduladores de los receptores A3 de adenosina |
| CN108137547B (zh) | 2015-08-03 | 2021-11-12 | 百时美施贵宝公司 | 可用作TNFα调节剂的杂环化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE265143C (enExample) | ||||
| FR2582514B1 (fr) * | 1985-05-30 | 1988-02-19 | Rhone Poulenc Sante | Medicaments a base d'amides, nouveaux amides et leur preparation |
| JPH01180518A (ja) * | 1988-01-12 | 1989-07-18 | Nissan Chem Ind Ltd | 配向処理剤 |
| IL111266A (en) * | 1993-10-22 | 2002-03-10 | Zeneca Ltd | 2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| CA2370264A1 (en) * | 1999-04-23 | 2000-11-02 | Takeda Chemical Industries, Ltd. | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof |
-
2002
- 2002-05-29 US US10/478,721 patent/US6969723B2/en not_active Expired - Fee Related
- 2002-05-29 AU AU2002304358A patent/AU2002304358B2/en not_active Ceased
- 2002-05-29 EA EA200301317A patent/EA006854B1/ru not_active IP Right Cessation
- 2002-05-29 MX MXPA03010870A patent/MXPA03010870A/es active IP Right Grant
- 2002-05-29 HR HRP20031091AA patent/HRP20031091B1/xx not_active IP Right Cessation
- 2002-05-29 WO PCT/HU2002/000048 patent/WO2002096879A1/en not_active Ceased
- 2002-05-29 EP EP02732985A patent/EP1390349B1/en not_active Expired - Lifetime
- 2002-05-29 PL PL02366516A patent/PL366516A1/xx not_active Application Discontinuation
- 2002-05-29 KR KR1020037015646A patent/KR100745307B1/ko not_active Expired - Fee Related
- 2002-05-29 CZ CZ20033510A patent/CZ20033510A3/cs unknown
- 2002-05-29 CN CNB02810840XA patent/CN1257160C/zh not_active Expired - Fee Related
- 2002-05-29 RU RU2003137836/04A patent/RU2278112C2/ru not_active IP Right Cessation
- 2002-05-29 BR BR0209719-2A patent/BR0209719A/pt not_active IP Right Cessation
- 2002-05-29 NZ NZ529966A patent/NZ529966A/en not_active IP Right Cessation
- 2002-05-29 RS YUP-950/03A patent/RS95003A/sr unknown
- 2002-05-29 IL IL15885402A patent/IL158854A0/xx not_active IP Right Cessation
- 2002-05-29 JP JP2003500059A patent/JP4409935B2/ja not_active Expired - Fee Related
- 2002-05-29 EE EEP200300574A patent/EE05304B1/xx not_active IP Right Cessation
- 2002-05-29 CA CA2448561A patent/CA2448561C/en not_active Expired - Fee Related
- 2002-05-29 SK SK1414-2003A patent/SK14142003A3/sk unknown
- 2002-05-31 AR ARP020102036A patent/AR036074A1/es unknown
-
2003
- 2003-07-08 TN TNPCT/HU2002/000048A patent/TNSN03117A1/en unknown
- 2003-11-10 MA MA27388A patent/MA26236A1/fr unknown
- 2003-11-26 IS IS7052A patent/IS2773B/is unknown
- 2003-11-28 NO NO20035300A patent/NO327710B1/no not_active IP Right Cessation
- 2003-12-05 CO CO03107462A patent/CO5550457A2/es not_active Application Discontinuation
- 2003-12-19 BG BG108477A patent/BG108477A/bg unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004536074A5 (enExample) | ||
| KR850000630B1 (ko) | 피페리딘 유도체의 제조방법 | |
| KR100357411B1 (ko) | 테트라시클릭유도체,제조방법및용도 | |
| US6352989B1 (en) | Nitrogenous heterocyclic derivatives and medicine thereof | |
| JPWO2015088000A1 (ja) | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 | |
| JP2005534706A5 (enExample) | ||
| JP2001511781A (ja) | スルホンアミド誘導体 | |
| RU2003137836A (ru) | Производные аминохинолина и его применение в качестве лигандов аденозина а3 | |
| CN112272553A (zh) | 取代的苯并呋喃、苯并吡咯、苯并噻吩及结构相关的补体抑制剂 | |
| FR2767826A1 (fr) | Derives d'amines cycliques, compositions pharmaceutiques les contenant, procedes pour les preparer, et leur utilisation en tant que principe pharmaceutique agissant contre les maladies respiratoires | |
| TW200526574A (en) | Pyrrole and pyrazole compounds | |
| WO2014196793A1 (en) | Heterocyclic derivatives and use thereof | |
| SK2962002A3 (en) | Carboxylic acid amides, medicaments containing these compounds and the use and production thereof | |
| CN1339435A (zh) | 制备西酞普兰的方法 | |
| HUP9903797A2 (hu) | Benzofurán-karboxamidok és -szulfonamidok, alkalmazásuk gyógyszerkészítmények előállítására és ezek a gyógyszerkészítmények | |
| JPS636058B2 (enExample) | ||
| JP2006515572A5 (enExample) | ||
| JP3204456B2 (ja) | ２，７―置換オクタヒドロ―ピロロ［１，２―ａ］ピラジン誘導体 | |
| KR20020030268A (ko) | 모노플루오로알킬 유도체 | |
| CA2534105A1 (en) | Aminoquinoline derivatives and their use as adenosine a3 ligands | |
| US6339087B1 (en) | Cyclic amine derivatives-CCR-3 receptor antagonists | |
| JP2005516956A5 (enExample) | ||
| JP6518692B2 (ja) | 多環式ｈｅｒｇ活性化剤 | |
| JPS6257606B2 (enExample) | ||
| TW201522288A (zh) | α－取代甘胺醯胺衍生物 |